Sleep apnea syndrome: experience of the pulmonology department in Ibn Sina Hospital, Rabat, Morocco

Asmaa Jniene1,4, Mustapha el Ftouh1, Mohamed Tawfiq el Fassy Fihry1

1Department of pulmonology, Ibn Sina hospital, Rabat, Morocco
4Corresponding author: Asmaa Jniene, Department of pulmonology, Ibn Sina hospital, Rabat, Morocco

Key words: Obstructive sleep apnea hypopnea syndrome, characteristics, management, reliability, Berlin questionnaire, Epworth sleepiness scale

Received: 1/13/2012 - Accepted: 7/28/2012 - Published: 10/10/2012

Abstract

Introduction
Sleep apnea syndrome is a highly prevalent disorder that is still underdiagnosed and undertreated and whose obstructive form is the most common. The diagnosis is suspected on clinical signs collected by interrogation and questionnaires (Berlin questionnaire and Epworth sleepiness scale), then confirmed by objective sleep study findings (polygraphy or polysomnography). It is necessary to conduct studies in each context on the characteristics and management of sleep apnea syndrome comprising the testing of reliability of the questionnaires.

Methods
Prospective and descriptive study of 104 patients addressed to sleep consultation at pulmonology Department of Ibn Sina Hospital, Morocco over a period of 5 years (January 2006 to December 2010), agreed to participate in the study, responded to a predetermined questionnaire, and benefited from clinical examination and paraclinical tests including a polygraphy or a polysomnography.

Results
59 (56.7%) patients had an obstructive sleep apnea-hypopnea syndrome with a similar prevalence in both sexes. 32.2% of patients were obese and 28.8% had cardio-vascular diseases. Snoring, excessive daytime sleepiness and witnessed apnea were found in respectively 79.7%, 50.8% and 16.9%. Berlin questionnaire and Epworth sleepiness scale had an acceptable internal consistency against apnea hypopnea index with a Cronbach’s alpha coefficient respectively 0.79 and 0.78. Depending on severity, clinical impact and results of investigations, the adequate treatment has been proposed based on the 2010 recommendations for clinical practice.

Conclusion
This study has provided an idea about the profile and the management of patients having an obstructive sleep apnea-hypopnea syndrome and showed that both Berlin questionnaire and Epworth sleepiness scale are two simple and reliable methods in our context. A larger and further study across the country should be considered.
Introduction

The sleep apnea syndrome (SAS) is a highly prevalent disorder occurring in at least 4% of males and 2% of females [1-3], which results in periods of recurrent reduced breathing (hypopnea) or periods of breathing cessation (apnea). The most common form of sleep apnea is called obstructive sleep apnea-hypopnea syndrome (OSAHS) and is caused by the partial or complete collapse of the upper airway during sleep that leads to oxyhemoglobin desaturation and terminate by brief microarousals causing sleep fragmentation and alteration of its quality [4].

Patients habitually present with usual loud snoring, witnessed apnea and excessive daytime sleepiness (EDS). The diagnosis is based on combined assessment of clinical features with objective sleep study findings by polygraphy or polysomnography [5].

Untreated OSAHS increases the risk for car accidents [6], and worsens quality of life and mood [7]. However, the major health risk is represented by cardiovascular events whether acute (stroke, myocardial infarction and nocturnal sudden death) or chronic (systemic hypertension, coronary artery disease and heart failure) [8]. On the other hand, patients with OSAHS have a high prevalence of other cardiovascular risk factors that is obesity, hyperlipidemia, and diabetes (metabolic syndrome) [9].

Since the original description by Sullivan and coworkers in 1983 of continuous positive airway pressure (CPAP) treatment, it remains the mainstay of treatment for moderate to severe OSAHS in adults [10-13]. Effective treatment of the disorder has been associated with major improvements in quality of life and also a diminished risk of cardiovascular morbidity and mortality [14].

Despite the growing importance due to its high prevalence, its social and health repercussions, and its clear link to cardiovascular disease, the OSAHS is still frequently underdiagnosed and undertreated that's why epidemiological studies should be done in each population and context in order to emphasize the recognition of the disease, to describe its characteristics and management, also to test the reliability of its principal questionnaires (Berlin questionnaire and the Epworth sleepiness scale ESS) which constitute an initial step in the diagnosis since they may prioritize patients for polygraphy or polysomnography depending on their results.

Methods

Study population

This study was a prospective and descriptive analysis of records of 104 patients complaining of sleep disorders and addressed to the sleep consultation in the pulmonology department of Ibn Sina Hospital in Rabat (Morocco) over a period of 5 years (January 2006 to December 2010).
Oral consent was obtained from all patients for inclusion in the study. Authorization to conduct the study was provided by the hospital authorities.

Detailed information was recorded by a pulmonologist:

**Clinical information:** Provenance and epidemiological characteristics (age, sex, medical coverage); clinical history, median duration between the onset of symptoms and consultation, research of diurnal (daytime sleepiness, fatigue on awakening, headache, memory loss, decreased concentration, depression, irritability) and nocturnal symptoms (snoring, witnessed apnea, fragmented sleep, nocturia, sweating); estimated probability of clinical sleep disorders by Berlin questionnaire which consists of 3 categories related to the risk of having sleep apnea. When there are at least 2 positive categories it is in favor of a strong probability of the disease; Epworth Sleepiness Scale which is a scale intended to measure daytime sleepiness by use of a very short questionnaire that asks the subject to rate the probability of falling asleep on a scale of increasing probability from 0 to 3 for eight different situations. The scores are added together to obtain a single number. A score above 10 is considered in favor of EDS which can be associated to sleep disorders.

A complete clinical examination including a specialized ear, nose and throat examination (ENT) and also the calculation of body mass index (BMI) by the weight (kg) / size (m²). The World Health Organization defines overweight as a BMI equal to or greater than 25 kg/m² and obesity as a BMI equal to or greater than 30 kg/m².

**Paraclinical examination:** All the patients underwent a chest X-ray, spirometry and electrocardiogram. The patients also had a polygraphy or polysomnography according to the clinical probability of SAS which was based on the interrogation (presence and / or frequency of occurrence of the main signs suggestive of the SAS), the ESS and the Berlin questionnaire. When the probability was high or low and in the absence of neurologic signs, the patients had underwent polygraphy. When the diagnosis was uncertain or when the probability was medium or in the presence of neurologic signs, the polysomnography was performed.

Standard overnight polygraphy included airflow that was measured by a nasal pressure transducer, respiratory effort by thoracoabdominal belts, and arterial oxyhemoglobin saturation by a pulse oximeter placed on the patient’s finger. Polysomnography included in addition to these measurements, the recordings of electroencephalogram, electro-oculogram, submental myogram, and electrocardiogram.

Apnea was defined as the absence of the airflow over 10 seconds. An obstructive apnea was defined as the absence of airflow in the presence of rib cage and/or abdominal movements, and a central apnea was defined as the absence of both airflow and rib cage and abdominal movements. Events were scored as hypopneas when there was a decrease of at least 50% of a validated flow signal from the baseline or decrease below 50% or appearance of inspiratory plateau associated with a transcutaneous desaturation of at least 3% or when an electroencephalogram microarousal occurred [15].
Both apnea and hypopnea are added and expressed as an index: apnea-hypopnea index (AHI) which is used to assess the severity of sleep apnea based on the total number of apneas and hypopneas per hour. The severity is classified mild when the AHI was ranged from 5 to 15/h, moderate when the range was 15 to 30, and severe when it was above 30. Depending on the severity, the clinical impact and the results of investigations, the adequate treatment has been proposed based on the 2010 recommendations for clinical practice [15].

Expression of results

Data entry and analysis was done using SPSS 17.0 for Windows® (SPSS Inc, Chicago, IL, USA). Data were expressed as mean ± standard deviation and range, and for data with skewed distribution as median and range. Relationships among continuous quantitative variables were evaluated using student’s t test and continuous qualitative variables by chi square test. Correlations between the ESS and AHI, and between Berlin questionnaire and AHI were determined by linear regression. Cronbach’s Alpha Coefficient measured the internal consistency. Coefficients above 0.7 are generally regarded as acceptable, 0.8 and above are good, and 0.9 and above are considered excellent. Differences were considered statistically significant if p was less than 0.05.

Results

Epidemiology

During the 5 years study period, a total of 104 patients were enrolled. The mean age of patients was 47.5 years ± 12.4 with a sex ratio 1/1. The mean age of patients with OSAHS was 47.4 years ± 13 and 29 (49%) of the patients were female among whom 15 (51.7%) were postmenopausal. 44 patients (42.3%) had no medical coverage among whom 21 (35.6%) patients had OSAHS.

Clinical findings

The patients’ antecedents are represented by Table 1. The most reported diurnal and nocturnal signs are represented by Table 2. Berlin questionnaire: It was positive in favor of a strong probability of SAS in 50% of patients among whom 67.8% of the patients had OSAHS (p: 0.03). Berlin questionnaire had an acceptable internal consistency against apnea hypopnea index with a Cronbach’s alpha coefficient at 0.79. Epworth Sleepiness Scale: Averaged 10.1 ± 5.4 (range: 1-21). It was over 10 in favor of EDS in 60 subjects (57.7%) among whom 81.3% subjects had OSAHS (p: 0.04). ESS had an acceptable internal consistency against apnea hypopnea index with a cronbach’s alpha coefficient at 0.78. Data from the clinical examination are shown in Table 3.
Paraclinical examination

Data from the paraclinical examination are shown in Table 4. Polygraphy was performed in 64 subjects (61.5%), whereas the polysomnography was performed in 40 subjects (38.5%). 59 (56.7%) patients had an OSAHS among which 19 was mild, 20 moderate and 20 severe. No positional OSAHS nor central apnea syndrome were diagnosed. Among the severe OSAHS, 1 case of obesity-hypoventilation syndrome associated was recorded.

Treatment

Depending on the severity, the clinical impact and results of investigations, therapeutic approaches have been proposed: All overweight patients whose BMI exceeded 25 Kg/m² received dietary guidelines and were referred to a dietician whether or not they had a sleep-related breathing disorder. 5 patients were readressed to ENT consultation to receive a tonsillectomy before considering a mandibular advancement device or a CPAP. No indication for surgery was retained. Mild OSAHS received dietary guidelines. Moderate OSAHS received CPAP or mandibular advancement device as first-line, these were sent to a specialized dentist. As concern severe OSAHS, they had received CPAP as first-line and were sent to a specialized service provider. The patient with the association of OSAHS and obesity hypoventilation syndrome had beneficed of a non-invasive ventilation initially. Patients with asthma and / or associated with allergic rhinitis had received specific treatment for their respiratory disease. Patients with gastroesophageal reflux disease had received inhibitors of proton pump. All patients with OSAHS had benefited from therapeutic education in order to emphasize about the benefits and the correct compliance to treatment. All the patients were readressed to their home consultations for monitoring and receiving specific treatment of their primary pathology (consultation of Cardiology, ENT, endocrinology, neurology, nephrology and psychiatry).

Evolution

Was marked by the low number of patients returning for follow-up consultation: Only 9 (15.3%) patients with OSAHS had benefitted of a control by polygraphy among whom 7 were treated by CPAP, one by non invasive ventilation and one by mandibular advancement device. The control had objectified a normalization of the AHI, and also the quality of life and a reduction in daytime sleepiness objectified by the normalization of the ESS. The other patients were lost to sight.

Discussion

The SAS is a new disease that has been individualized until 1976 by Guilleminault et al. [16]. Among the well recognized risk factors in the development of the disease, the male gender is well known where the risk is two to three times higher in the general population. This increased
risk may be related to differences in the distribution of adipose tissue in men which have a central repository fat mainly around the neck, trunk and abdominal viscera comparing to women. Otherwise, preliminary data from the study cohort of Wisconsin (541 women aged 30 to 60 years) showed that menopause seems to be a risk factor for OSAHS and hormone therapy has a protective action [17].

In adults, the prevalence of OSAHS also increases with age. In the study of Ancoli-Israel et al. which included 427 subjects over 65 years, the frequency of an AHI higher than 10 was 70% for men and 56% for women, that was 3 times higher comparing to middle-aged adults [18]. Duran et al. have made similar findings [19]. Overweight and especially obesity is also a risk factor for conventional SAHOS. Indeed, mild to moderate obesity was associated with a significantly increased prevalence of sleep apnea [20] with an average body mass index of 30-35 kg/m2 in most recent series of literature [3,21].

Our study involved a population suspected sleep apnea syndrome addressed in sleep consultation, there was no sex predominance, among women 51.7% were postmenopausal, the average age of patients was 47.4 years ± 1 and the mean BMI was 30.6 kg/m² ±7.6.

Currently recognized and considered as a real public health problem, the SAHOS, in addition to its frequency, leads to an increase of cardiovascular, endocrine and psychic morbidity and mortality in addition to the significant increased risk of occupational and highway accidents. Indeed, there is an independent risk for the development of hypertension especially resistant to treatment, also coronary artery disease, heart failure and stroke [22-31]. It has been observed in patients with severe untreated OSAHS with CPAP, a significantly increased cardiovascular morbidity and mortality compared to controls, whereas those treated with CPAP, it is comparable to those of the general population [32].

In our study 17 (28.8%) patients with OSAHS had cardiovascular antecedents represented mainly by hypertension. Otherwise SAHOS increases by 40% the risk of developing the metabolic syndrome, which is in itself a cardiovascular risk factor [33-35]. Also, acromegaly and hypothyroidism represent the most classically endocrine disorders associated to OSAHS related to macroglossia encountered in these diseases and craniofacial abnormalities associated to acromegaly. Other conditions such as Cushing´s syndrome have been described in association with the disease [35].

In our study, among subjects with OSAHS 9 (15.3%) were diabetics, 6 (10.2%) had acromegaly, 2 (3.4%) had hypothyroidism and 1 (1.7%) was treated for hyperlipidemia.

EDS lead to psychological consequences represented by significant deficiencies in the quality of life, cognitive performance, and social functioning [7,36,37]. 14 (23.7%) of our patients had irritability from whom 2 reported a chronic depression under treatment. EDS is also the source of accidentological risk where the relative risk among patients with SAS compared to the general population is increased by a factor of 3 to 7. 1 patient reported a serious car accident because of his sleep while driving.
Under CPAP treatment, the disappearance of this EDS is associated to a significant improvement in quality of life [38,39] and a very significant reduction in accidents. A study showed that current smokers had a risk three times greater of developing OSAHS than subjects who never smoked, but these results were not confirmed and smoking cannot be considered as an established risk factor for OSAHS. Appropriate epidemiological studies are needed [40]. In our study, 12 (20.3%) of patients with OSAHS were smokers. Rhinitis is a risk factor for developing an OSAHS because of the local inflammation and congestion. 9 (15.3%) of patients with OSAHS had rhinitis in our study. Chronic renal failure is associated with the SAS but the mechanisms underlying this association are still unclear [41]. In our study, 2 (3.4%) patients with OSAHS was at the terminal stage of chronic renal failure. Finally, during OSAHS, swallowing reflex is impaired. A relationship between apnea and gastroesophageal reflux disease (GERD) is found. The number of episodes of reflux is reduced by positive airway pressure and number of awakenings on apnea is reduced by anti-H₂ [42]. In our study 2 (3.4%) had GERD.

The most common clinical signs in the SAHOS are represented by EDS, snoring and witnessed apnea. When examining a patient suspected of the disease, it is highly recommended to ask the partner who can often provide important additional information based on direct observation of the patient during his sleep [3,43].

Although sleep apnea is the most common cause of EDS, this taken alone cannot be a criterion for discrimination of clinical disorder, indeed between 30 and 50% of the general population report a significant sleepiness because study participants often confuse fatigue and EDS. On the other hand, several studies have shown that the severity of sleep apnea and EDS did not match [44] since many other sleep disorders can also cause EDS.

Snoring is a very common sign in the general population whose prevalence is increasing in both sexes after 35 years. It is assumed that 60% of men and 40% of women aged 40 to 60 are habitual snorers. That is why taken alone, snoring is not considered synonymous to SAHOS but when it is regularly interrupted by apneas and it reappears in an intense way for the resumption of breathing it is very suggestive of the disease [45].

As concern apnea, it should be noted that it is a good predictor sign but does not predict the severity of the disease [45]. Fragmented sleep is frequently reported by patients, it reflects the effect of recurrent arousals. In our study, 47 (79.7%) patients reported snoring 10 (16.9%) a witnessed apnea, and 12 (20.3%) a fragmented sleep.

The severity of EDS can be evaluated subjectively by various questionnaires; the most widely used is the ESS [44]. It was introduced in 1991 by Dr Murray Johns of Epworth Hospital in Melbourne, Australia. The Berlin questionnaire is an instrument validated to use in the western population to determine the occurrence of risk factors for OSA, namely snoring behavior, wake-time sleepiness or fatigue, and the presence of obesity or hypertension. The predictive performance of the Berlin questionnaire has been evaluated in the population of Cleveland, Ohio, with a sensitivity of 86% and specificity of 77% [46].
In the present study, the reliability of these two questionnaires was tested and showed that they are two simple and reliable methods for measuring daytime sleepiness and identifying patients who are likely to have sleep apnea.

On physical examination, and more specifically the ENT examination, the most frequently encountered abnormality is the oropharyngeal narrowing with or without an increase in deposits of soft tissues [47]. This was the most frequently found in the study in addition to macroglossia and big tonsils.

Polysomnography is considered the gold standard for the diagnosis of OSAHS. However, the access is restricted due to its high cost, the need for continuous attention, and a considerable investment of time on the part of medical staff. In the present study we performed polysomnography in patients when the diagnosis was uncertain or when the probability was medium or in the presence of neurologic signs. Otherwise, the polygrapy was performed. The indication for treatment was based on the 2010 french recommandations for clinical practice [15].

**Conclusion**

The present study has given a brief idea on the characteristics, the management of patients who suffer from OSAHS and also shown an acceptable reliability of the Berlin questionnaire and the ESS in this sample of Moroccan population. Nevertheless, there are limitations. First it only shows the characteristics of OSAHS in a group of subjects being aware of their condition health, living mainly in big cities of Morocco. Second it is limited by the low number of patients’ recruitment that may be due to sleep medicine which is still in a stage of development in Morocco and SAS is frequently under-diagnosed and still underestimated not only by the public but also by the medical community. In the other hand it may be explained by the difficulty to access to diagnosis (examination cost for subjects with no Medical coverage). And finally the number of patients returning for follow-up consultation was very low. A larger study across the country should be considered.

**Competing interests**

The authors declare no competing interests.
Authors’ contributions

All the authors have contributed to this study in ways that conform to the ICMJE authorship criteria. All the authors have read and approved the final version of the manuscript.

Tables

Table 1: The patients’ antecedents (A: all subjects, n = 104; B: patients with OSAHS, n= 59)

Table 2: The most reported clinical signs (A: all subjects, n = 104; B: patients with OSAHS, n= 59)

Table 3: Data from the clinical examination (A: all subjects, n = 104; B: patients with OSAHS, n= 59)

Table 4: Data from the paraclinical examination (A: all subjects, n = 104; B: patients with OSAHS, n= 59)

References

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328 : 1230-1235. This article on PubMed
2. Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):685-9. This article on PubMed
3. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002; 165:1217-1239. This article on PubMed
4. Deegen PC, Mc Nicholas WT. Pathophysiology of obstructive sleep apnea. Eur Respir J. 1995; 8:1161-1178. This article on PubMed
5. Flemons WW, Littner MR, et al. Home diagnosis of sleep apnea: a systematic review of the literature: An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest. 2003 Oct;124(4):1543-79. This article on PubMed
6. George CFP. Sleep 5: Driving and automobile crashes in patients with obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004; 59: 804-807. This article on PubMed
7. Engleman HM, Douglas NJ. Sleep 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004; 59:618-622. This article on PubMed
8. McNicholas WT, Bonsigore MR; Management Committee of EU cost action B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007; 29:156-178 . This article on PubMed
9. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002; 106:286-8. This article on PubMed
10. Sullivan CE, Issa FG, Berthon-Jones M, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet. 1981; 1: 862-865. [This article on PubMed]

11. Loube DI, Gay PC, Strohl KP, et al. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest. 1999; 115:863-866. [This article on PubMed]

12. Gay P, Weaver T, Loube D, et al. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep. 2006; 29:381-401. [This article on PubMed]

13. Kushida CA, Littner MR, Hirshkowitz M, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006; 29:375-380. [This article on PubMed]

14. Doherty LS, Kiely JL, Swan V, Mc Nicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest. 2005; 127: 2076-2084. [This article on PubMed]

15. Recommandations pour la pratique clinique. Syndrome d'apnées hypopnées obstructives du sommeil de l'adulte. Revue des Maladies Respiratoires. 2010; 27: 806-833. [This article on PubMed]

16. Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. Annu Rev Med. 1976; 27: 465-84. [This article on PubMed]

17. Bixler E, Vgontzas A, Lin H, Ten Have T, Reij N, Vela-Buen A, Kales A. Prevalence of sleep-disordered breathing in women. Am J Respir Crit Care Med. 2001; 163: 608-13. [This article on PubMed]

18. Ancoli-Israel S, Kripke D, Klauber M, Mason W, Fell R, Kaplan O. Sleep-disordered breathing in community-dwelling elderly. Sleep. 1991; 14: 486-95. [This article on PubMed]

19. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med. 2001; 163: 685-9. [This article on PubMed]

20. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000; 284:3015-3021 . [This article on PubMed]

21. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol. 2005; 99: 1592-1599. [This article on PubMed]

22. McNicholas WT, Bonsigore MR; Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007 Jan;29(1):156-78. [This article on PubMed]

23. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D’Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA. 2000; 283: 1829-1836. [This article on PubMed]

24. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342: 1378-1384. [This article on PubMed]

25. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353: 2034-2041. [This article on PubMed]

26. McArdle N, Riha RL, Vennelle M, Coleman EL, Dennis MS, Warlow CP, Douglas NJ. Sleep-disordered breathing as a risk factor for cerebrovascular disease: a case-control study in patients with transient ischemic attacks. Stroke. 2003; 34: 2916-2921. [This article on PubMed]

27. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J. 2006; 28: 596-602. [This article on PubMed]

28. Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U. Sleep disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med. 2001; 164 :1910-1913. [This article on PubMed]

29. Logan AG, Perlikowski SM, Mente A et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001 Dec;19(12):2271-7. [This article on PubMed]
30. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ. 2000; 320: 479-482. This article on PubMed
31. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of Sleep-disordered Breathing and the Occurrence of Stroke. American Journal of Respiratory and Critical Care Medicine. 2005; 172: 1447-1451. This article on PubMed
32. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25;365(9464):1046-53. This article on PubMed
33. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE; Sleep Heart Health Study Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004; 160: 521-530. This article on PubMed
34. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med. 2005; 172 :1590-1595. This article on PubMed
35. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004; 25: 735-741. This article on PubMed
36. Meurice JC. Circonstances de diagnostic du syndrome d'apnées du sommeil et ses complications. Revue des Maladies Respiratoires. 2004; 21: 43-48. This article on PubMed
37. Akashiba T, Kawahara S, Akahoshi T, Omori C, Saito O, Majima T, Horie T. Relationship between quality of life and mood or depression in patients with severe obstructive sleep apnea syndrome. Chest. 2002; 122: 861-865. This article on PubMed
38. Skobel E, Norra C, Sinha A, Breuer C, Hanrath P, Stellbrink C. Impact of sleep-related breathing disorders on health-related quality of life in patients with chronic heart failure. Eur J Heart Fail. 2005; 7: 505-11. This article on PubMed
39. Jenkinson C, Stradling J, Petersen S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airway pressure therapy for sleep apnoea. J Sleep Res. 1997; 6: 199-204. This article on PubMed
40. Wetter DW, Young TB, Bidwell TR, Dadr MS, Palta M. Smoking as a risk factor for sleep-disordered breathing. Arch Intern Med. 1994; 154: 2219-24. This article on PubMed
41. Beecroft JM, Hoffstein V et al. Nocturnal haemodialysis increases pharyngeal size in patients with sleep apnoea and end-stage renal disease. Nephrol Dial Transplant. 2008 Feb;23(2):673-9. This article on PubMed
42. Chabot F. Gastroesophageal reflux. Rev Mal Respir. 2002 Oct;19(5 Pt 2):S91-S. This article on PubMed
43. Kingshott RN, Sime PJ, Engleman HM, Douglas NJ. Self assessment of daytime sleepiness: patient versus partner. Thorax. 1995; 50: 994-995. This article on PubMed
44. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991; 14: 540-545. This article on PubMed
45. Deegan PC, McNicholas WT. Predictive value of clinical features for the obstructive sleep apnoea syndrome. Eur Respir J. 1996 Jan;9(1):117-24. This article on PubMed
46. Saleh AM, Ahmad MA, Awadalla NJ. Development of Arabic version of Berlin questionnaire to identify obstructive sleep apnea at risk patients. Ann Thorac Med. 2011; 6: 212-21647. This article on PubMed
47. Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnea. Eur Respir J. 1995 Jul;8(7):1161-78. This article on PubMed
**Table 1:** The patients’ past medical history of patients with obstructive sleep apnea-hypopnea syndrome seen at the pulmonology department of Ibn Sina Hospital, Rabat, Morocco from January 2006 to December 2010

| Category                  | Number a (%) | Number b (%) |
|---------------------------|--------------|--------------|
| **Cardiovascular**        |              |              |
| Hypertension              | 28 (26.9)    | 17 (28.8)    |
| Ventricular extrasystole  | 2 (1.9)      | 1 (1.7)      |
| Arrhythmia                | 3 (2.9)      | 2 (3.4)      |
| **Endocrine**             |              |              |
| Cushing                   | 1 (1)        | 0            |
| Thyroid nodule            | 3 (2.9)      | 2 (3.4)      |
| Acromegaly                | 11 (10.6)    | 6 (10.2)     |
| Goiter                    | 6 (5.8)      | 5 (8.5)      |
| Hypothyroidism            | 2 (1.9)      | 2 (3.4)      |
| Diabetes                  | 22 (21.2)    | 9 (15.3)     |
| Hyperlipemia              | 2 (1.9)      | 1 (1.7)      |
| **Pulmonary**             |              |              |
| Asthma                    | 4 (3.9)      | 1 (1.7)      |
| Pulmonary fibrosis        | 1 (1)        | 0            |
| Smoking                   | 15 (14.4)    | 12 (20.3)    |
| **ENT**                   |              |              |
| Allergic rhinitis         | 14 (13.5)    | 9 (15.3)     |
| Chronic sinusitis         | 4 (3.9)      | 1 (1.7)      |
| Tonsillectomy             | 3 (2.9)      | 1 (1.7)      |
| Uvulo-palato-pharyngoplasty | 1 (1)    | 0            |
| **Neuropsychiatric**      |              |              |
| Epilepsy                  | 1 (1)        | 0            |
| Chronic migraine          | 2 (1.9)      | 1 (1.7)      |
| Chronic depression        | 2 (1.9)      | 1 (1.7)      |
| **Nephrological**         |              |              |
| Renal failure             | 2 (1.9)      | 2 (3.4)      |
| **Gastrointestinal**      |              |              |
| Gastroesophageal reflux   | 8 (7.7)      | 2 (3.4)      |
| **Dysmorphic craniofacial defects** |  |  |
| Mac cune Albright syndrom | 1 (1)        | 1 (1.7)      |
| Craniosynostosis in Apert type with Arnold Chiari malformation type 1 | 1 (1) | 1 (1.7) |
| Achondroplasia            | 1 (1)        | 1 (1.7)      |
| **Highway accidents**     | 3 (2.9)      | 1 (1.7)      |

*a: all subjects, n = 104; b: patients with obstructive sleep apnea-hypopnea syndrome, n= 59*
Table 2: The most reported clinical signs in patients with obstructive sleep apnea-hypopnea syndrome seen at the pulmonology department of Ibn Sina Hospital, Rabat, Morocco from January 2006 to December 2010

| Clinical signs               | Number<sup>a</sup>(%) | Number<sup>b</sup>(%) |
|-----------------------------|------------------------|------------------------|
| **Diurnal signs**           |                        |                        |
| Daytime sleepiness          | 53 (51)                | 30 (50,8)              |
| fatigue on awakening        | 35 (33,7)              | 20 (33,9)              |
| Headache                    | 26 (25)                | 18 (30,5)              |
| Irritability                | 25 (24)                | 14 (23,7)              |
| Decreased concentration     | 23 (22,1)              | 12 (20,3)              |
| Memory Loss                 | 17 (16,3)              | 9 (15,3)               |
| Depression                  | 19 (18,3)              | 3 (5,1)                |
| **Nocturnal signs**         |                        |                        |
| Snoring                     | 77 (74)                | 47 (79,7)              |
| Witnessed Apnea             | 39 (37,5)              | 10 (16,9)              |
| Fragmented Sleep            | 15 (14,4)              | 12 (20,3)              |
| sweating                    | 14 (13,5)              | 9 (15,3)               |
| Nocturia                    | 10 (9,6)               | 5 (8,5)                |

<sup>a</sup>: all subjects, n = 104; <sup>b</sup>: patients with obstructive sleep apnea-hypopnea syndrome, n= 59
Table 3: Data from the clinical examination of patients with obstructive sleep apnea-hypopnea syndrome seen at the pulmonology department of Ibn Sina Hospital, Rabat, Morocco from January 2006 to December 2010

| Clinical examination | Number^a (%) | Number^b (%) |
|----------------------|--------------|--------------|
| **BMI (mean kg/m^2 ± standard deviation)** | 30,5 ± 6,9 | 30,6 ± 7,6 |
| **Pulmonary examination** | | |
| Normal | 103 (99) | 59 (100) |
| Abnormal (pulmonary fibrosis) | 1 (1) | 0 |
| **ENT examination** | | |
| Normal | 84 (80,8) | 47 (79,7) |
| Abnormal | 20 (19,2) | 12 (20,3) |
| Big tonsils | 5 (4,8) | 5 (5,8) |
| Dysmorphic syndrome with reduced antero-posterior pharynx | 5 (4,8) | 4 (6,8) |
| Macroglossia | 5 (4,8) | 4 (6,8) |
| Nasal septum deviation | 6 (5,8) | 2 (3,4) |
| Long soft palate | 4 (3,8) | 2 (3,4) |
| Oropharynx with small soft palate located below | 2 (1,9) | 1 (1,7) |
| Velar hypertrophy with thickening of the posterior pillars | 1 (1) | 1 (1,7) |
| Retrognathia, short neck and hypoplasia of the dentition of the lower jaw | 1 (1) | 1 (1,7) |
| **Cardiovascular examination** | | |
| Hypertension | 6 (5,8) | 4 (6,8) |
| **Examination of the thyroid gland** | | |
| Goiter | 4 (3,9) | 2 (3,4) |
| **Neurological examination** | | |
| Normal | 104 (100) | 0 |
| Abnormal | 0 | 0 |

^a: all subjects, n = 104; ^b: patients with obstructive sleep apnea-hypopnea syndrome, n = 59
Table 4: data from the paraclinical examination of patients with obstructive sleep apnea-hypopnea syndrome seen at the pulmonology department of Ibn Sina Hospital, Rabat, Morocco from January 2006 to December 2010

| Paraclinical findings                             | Number<sup>a</sup>(%) | Number<sup>b</sup> (%) |
|--------------------------------------------------|------------------------|------------------------|
| **Chest X ray**                                   |                        |                        |
| Normal                                           | 98 (94,2)              | 57 (96,6)              |
| Abnormal                                         | 6 (5,8)                | 3 (5,1)                |
| Cardiomegaly                                     | 2 (1,9)                | 1 (1,7)                |
| Enlargement of the superior mediastinum          | 3 (2,9)                | 1 (1,7)                |
| Interstitial Syndrome                            | 1 (1)                  | 0                      |
| **Spirometry**                                   |                        |                        |
| Normal                                           | 94 (90,4)              | 56                     |
| Restrictive profile                              | 7 (6,7)                | 1 (1,7)                |
| Obstructive ventilatory defect                   | 3 (2,9)                | 2 (3,4)                |
| **Electrocardiogram**                            |                        |                        |
| Normal                                           | 92 (88,5)              | 54                     |
| Abnormal                                         | 12 (11,5)              | 5 (8,5)                |
| Right atrial hypertrophy                         | 10 (9,6)               | 4 (6,8)                |
| Arrhythmia                                       | 2 (1,9)                | 1 (1,7)                |

<sup>a</sup>: all subjects, n = 104; <sup>b</sup>: patients with obstructive sleep apnea-hypopnea syndrome, n= 59